Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
E413550-5mg | 5mg | In stock | $53.90 | |
E413550-10mg | 10mg | In stock | $86.90 | |
E413550-25mg | 25mg | In stock | $162.90 | |
E413550-50mg | 50mg | In stock | $271.90 | |
E413550-100mg | 100mg | In stock | $489.90 | |
E413550-250mg | 250mg | In stock | $1,102.90 |
PORCN Inhibitors
Synonyms | ETC-159 | 1638250-96-0 | ETC-1922159 | 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide | ETC159 | 2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide | CHEMBL3633802 | 5L854240DQ | 7H-Purine-7-acetamide |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | ETC-159 (ETC-1922159) is an orally available, potent porcupine inhibitor with an IC50 of 2.9 nM for inhibiting β-catenin reporter activity in STF3A cells. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of porcupine O-acyltransferase |
Product Description | Information ETC-159 ETC-159 (ETC-1922159) is an orally available, potent porcupine inhibitor with an IC50 of 2.9 nM for inhibiting β-catenin reporter activity in STF3A cells. Targets Porcn In vitro ETC-159 treatment causes decreased abundance of Wnt3a-stabilized β-catenin protein in both mouse L cells and HEK293 cells. ETC-159 inhibits β-catenin signaling in response to multiple active Wnts. ETC-159 inhibits mouse PORCN with an IC50 of 18.1\u2009nM, whereas the IC50 for Xenopus Porcn is approximately fourfold higher (70\u2009nM). In vivo ETC-159 is orally bioavailable and effectively inhibits the growth of mouse mammary tumor virus-Wnt1 tumors. After a single oral dose of 5\u2009mg/kg in mice, ETC-159 is rapidly absorbed into the blood with a Tmax of ~0.5\u2009h and oral bioavailability of 100%. The plasma half-life is ~1.18\u2009h and its concentration in the blood remained above the in vitro IC50 for at least 16\u2009h. Treatment of mice with increasing doses of ETC-159 leads to a dose-related increase in exposure. ETC-159 also effectively inhibits Wnt autocrine signaling and growth of teratocarcinomas. ETC-159 effectively inhibits the growth and induces differentiation of colon cancers with RSPO translocations and induces global remodeling of gene expression. Suppression of Wnt/β-catenin signaling with ETC-159 in genetically defined tumors induces irreversible cellular differentiation thus preventing regrowth of these tumors. Cell Research(from reference) Cell lines:Mouse L cells Concentrations:100\u2009nM Incubation Time:0-24 h |
ALogP | 1.404 |
---|---|
HBD Count | 1 |
Rotatable Bond | 4 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide |
---|---|
INCHI | InChI=1S/C19H17N7O3/c1-24-17-16(18(28)25(2)19(24)29)26(11-20-17)10-15(27)21-14-9-8-13(22-23-14)12-6-4-3-5-7-12/h3-9,11H,10H2,1-2H3,(H,21,23,27) |
InChi Key | QTRXIFVSTWXRJJ-UHFFFAOYSA-N |
Canonical SMILES | CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)NC3=NN=C(C=C3)C4=CC=CC=C4 |
Isomeric SMILES | CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)NC3=NN=C(C=C3)C4=CC=CC=C4 |
PubChem CID | 86280523 |
Molecular Weight | 391.38 |
PubChem CID | 86280523 |
---|---|
CAS Registry No. | 1638250-96-0 |
ChEMBL Ligand | CHEMBL3633802 |
BindingDB Ligand | 50133866 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
F23161265 | Certificate of Analysis | May 25, 2023 | E413550 |
F23161267 | Certificate of Analysis | May 25, 2023 | E413550 |
F23161268 | Certificate of Analysis | May 25, 2023 | E413550 |
F23161270 | Certificate of Analysis | May 25, 2023 | E413550 |
F23161271 | Certificate of Analysis | May 25, 2023 | E413550 |
F23161272 | Certificate of Analysis | May 25, 2023 | E413550 |
F23161274 | Certificate of Analysis | May 25, 2023 | E413550 |
F23161275 | Certificate of Analysis | May 25, 2023 | E413550 |
F23161276 | Certificate of Analysis | May 25, 2023 | E413550 |
F23161280 | Certificate of Analysis | May 25, 2023 | E413550 |
F2317272 | Certificate of Analysis | May 25, 2023 | E413550 |
F2317274 | Certificate of Analysis | May 25, 2023 | E413550 |
Solubility | Solubility (25°C) In vitro DMSO: 78 mg/mL (199.29 mM); Water: Insoluble; Ethanol: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 78 |
DMSO(mM) Max Solubility | 199.294803004752 |
Water(mg / mL) Max Solubility | <1 |
1. Ho SY, Keller TH. (2015) The use of porcupine inhibitors to target Wnt-driven cancers.. Bioorg Med Chem Lett, 25 (23): (5472-6). [PMID:26522946] |
2. Madan B, Ke Z, Harmston N, Ho SY, Frois AO, Alam J, Jeyaraj DA, Pendharkar V, Ghosh K, Virshup IH et al.. (2016) Wnt addiction of genetically defined cancers reversed by PORCN inhibition.. Oncogene, 35 (17): (2197-207). [PMID:26257057] |
3. Ho SY, Alam J, Jeyaraj DA, Wang W, Lin GR, Ang SH, Tan ESW, Lee MA, Ke Z, Madan B et al.. (2017) Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.. J Med Chem, 60 (15): (6678-6692). [PMID:28671458] |